TG Therapeutics price target raised to $20 from $17 at BofA
BofA analyst Alec Stranahan raised the firm's price target on TG Therapeutics to $20 from $17 and keeps an Underperform rating on the shares. TG Therapeutics' Q2 print will likely center on whether Briumvi continues to exceed elevated expectations, with focus on U.S. revenue performance versus company guidance of $220M and estimates of approximately $229M, the analyst tells investors in a research note.
BofA analyst Alec Stranahan raised the firm's price target on TG Therapeutics to $20 from $17 and keeps an Underperform rating on the shares.
TG Therapeutics' Q2 print will likely center on whether Briumvi continues to exceed elevated expectations, with focus on U.S. revenue performance versus company guidance of $220M and estimates of approximately $229M, the analyst tells investors in a research note.